Watch Dr. Bill Gray and Dr. Sahil Parikh discuss the significance of the PAD III RCT 1 & 2yr Results
Dr. Gray discussing DISRUPT PAD III results
Read the JSCAI Publication
JSCAI publication
PAD III Data Summary
DISRUPT PAD III data summary
Download Data Summary
Download

Disrupt PAD III is the largest-ever randomized study of severely calcified peripheral lesions

45
Global sites
306
SFA/Popliteal lesions randomized to IVL or PTA
83%
Severe calcification by PARC by an independent core-lab*
129mm
Average calcified length by an independent core-lab*

*Data refers to IVL arm of randomized study

SUPERIOR PREP

IVL’s unique mechanism of action delivers significantly more luminal gain with lower dilatation pressure and less need for post-dilatation

Superior Procedural Success

IVL procedural success bar graph

Atraumatic Treatment

IVL atraumatic treatment data

PRESERVED OPTIONS

IVL maintains control of the procedure by minimizing complications such as dissections, embolization, and perforations. IVL significantly reduces the need for bailout stents, preserving future treatment options.

Reduced Dissections

IVL 77% reduced dissections bar graph

Low Complications

0% embolization, perforation, thrombus, and no flow

Reduced Bailout Stenting

IVL 75% reduction in bailout stenting bar graph

EXCELLENT LONG-TERM RESULTS

IVL has demonstrated excellent patency out to two years in a severely calcified patient population

Primary Patency*

IVL primary patency percent over time line graph

*Primary Patency defined as freedom from provisional stenting at index procedure, freedom from clinically-driven target lesion revascularization, and freedom from restenosis determined by duplex ultrasound

plus-sign
m5logo

On The +Plus Side

See how the new faster, further, larger Shockwave M5+ can help treat your patients with calcified PAD

LEARN More
Shockwave M5 medical device

Ready to Make Waves with Shockwave IVL?

Looking for careers? Click here.

ico email Connect